Precipio, Inc. (PRPO) Q1 2025 Shareholder Update – Full Coverage скачать в хорошем качестве

Precipio, Inc. (PRPO) Q1 2025 Shareholder Update – Full Coverage

*Precipio, Inc. (PRPO) Q1 2025 Shareholder Update – Full Coverage* *Key Highlights:* *Financials* – Q1 2025 revenue $4.9M (+43% YoY, -9.5% QoQ), gross margin 43% (+16%), adjusted EBITDA loss $0.108M (-92% YoY), net cash used $0.372M (-49%), cash $0.4M CARES Act credit received. *Operations* – Pathology test volume +46%, revenue +53%, 11 new physicians; products division onboarded 1 customer, launched 2 panels; MoIDX approval adds ~$0.25M/quarter. *Strategy* – CEO Ilan Daniele emphasized pathology scale, product pipeline growth post-FDA LDT ruling reversal, and operational efficiency; targets positive cash flow in Q2/Q3 2025. *Outlook* – Expects Q2 revenue rebound, product sales growth, and continued margin gains (pathology ~45%, products ~51%); anticipates $1M more CARES Act funds, Change Healthcare settlement benefits. *Timestamps:* [00:00] – Opening Remarks and Safe Harbor [02:59] – Financial Performance Overview [04:26] – Pathology Services Division Update [07:03] – Operational Efficiency and Margin Gains [09:47] – Medicare MoIDX Approval Impact [11:05] – Products Division Progress [13:37] – FDA LDT Ruling Reversal [17:23] – Change Healthcare and CARES Act Funds [18:48] – 2025 Outlook and Closing *Keywords:* Precipio, Q1 2025 update, PRPO stock, pathology services, diagnostic products, MoIDX, CARES Act, FDA LDT, gross margin, cancer diagnostics *Buy, Hold, or Sell?* Precipio, Inc. (PRPO) is a **BUY**. Strong pathology growth, MoIDX approval, and product pipeline momentum outweigh seasonal Q1 dip and validation delays. *Max Position* – Allocate *3-5%* in a diversified portfolio. *Comment below with your thoughts! Subscribe for more updates!* *Full Details:* [Precipio Investor Relations](https://www.precipiodx.com/investors/) *Disclaimer:* This video includes segments from the shareholder update call by Precipio, Inc., used solely for educational and informational purposes under fair use (Section 107, US Copyright Act). No affiliation or endorsement by Precipio, Inc. is implied. All rights to the original content remain with the company. For the official call, visit [https://www.precipiodx.com/investors/](https://www.precipiodx.com/investors/). For inquiries or requests for removal, please contact us at [email protected].